Biosimilar patent litigation trends in the US

Biosimilares/General | Posted 05/03/2021 post-comment0 Post your comment

According to authors from Law360 the trend in biosimilar patent litigation cases has been downward, with many cases being resolved and only five cases still pending as of 31 December 2020 [1].

Law V13C29

In the US, the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) was signed into law on 23 March 2010, giving the US Food and Drug Administration (FDA) the authority to approve biosimilars via an abbreviated pathway.

The BPCI Act patent litigation procedures are triggered when FDA accepts an application for a biosimilar. Therefore, after the first biosimilar applications were submitted to FDA in 2014, patent litigation first started to appear in the US, reaching a peak in 2018, but tailing off afterwards.

Of the 29 BPCI Act patent litigation cases ever filed, 14 were settled and six concluded with a final judgment or dismissal during 2018‒2020 alone. In fact, during 2019‒2020 there have been 15 case conclusions, which far exceeds the six new filings and means that only five biosimilar patent litigation cases remain pending as of 31 December 2020.

Two litigation cases were concluded in 2020, both involving Genentech and Amgen and relating to trastuzumab, which is marketed by Genentech as Herceptin, and bevacizumab, marketed by Genentech as Avastin. Genentech reached a settlement agreement with Amgen over its trastuzumab and bevacizumab biosimilars dismissing all claims and allowing Amgen to continue marketing the biosimilars [2].

New litigation in 2020 included Amgen vs Hospira regarding the filgrastim biosimilar Nivestym (filgrastim-aafi) [3], Genentech vs Samsung Bioepis and Genentech vs Centus [4].

The authors expect the current lull in biosimilar litigation to be temporary and therefore with new biosimilars expected in 2021 new litigation will follow. Submission of biosimilar applications to FDA for previously un-litigated biosimilars, such as ranibizumab, aflibercept and insulin aspart, are expected to prompt litigation. While new litigation is also expected against adalimumab, bevacizumab, etanercept and pegfilgrastim biosimilars in 2021.

Related articles
Biosimilar approvals and launches in the US

Biosimilar approvals and patent litigation in the US


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. Whitehill J, Deshmukh J. After lull in biosimilar IP litigation, 2021 could bring influx. Law360. 2021 Jan 7.
2. GaBI Online - Generics and Biosimilars Initiative. Genentech and Amgen settle biosimilar disputes []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 5]. Available from: 
3. GaBI Online - Generics and Biosimilars Initiative. Amgen on both sides of the biosimilar arena []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 5]. Available from: 
4. GaBI Online - Generics and Biosimilars Initiative. Genentech sues Centus over Avastin biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 5]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Law360, US FDA

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010